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It is well accepted that Th17 cells are a highly plastic cell subset that can be easily directed
toward the Th1 phenotype in vitro and also in vivo during inflammation. However, there
is an ongoing debate regarding the reverse plasticity (conversion from Th1 to Th17). We
show here that ectopic ROR-γt expression can restore or initiate IL-17 expression by non-
classic or classic Th1 cells, respectively, while common pro-Th17 cytokine cocktails are
ineffective. This stability of the Th1 phenotype is at least partially due to the presence
of a molecular machinery governed by the transcription factor Eomes, which promotes
IFN-γ secretion while inhibiting the expression of ROR-γt and IL-17. By using a mouse
model of T cell-dependent colitis we demonstrate that Eomes controls non-classic Th1
cell development also in vivo and promotes their pathogenic potential. Eomes expression
associates to a highly inflammatory phenotype also in patients with juvenile idiopathic
arthritis. Indeed, it favors the acquisition of a cytotoxic signature, and promotes the
development of IFN-γ+GM-CSF+ cells that have been described to be pathogenic in chronic
inflammatory disorders.
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Introduction
Upon antigen encounter, na¨ıve CD4+ T helper (Th) cells acquire
specific effector functions to promote pathogen clearance. Three
main Th effector subsets have been described so far, which
are characterized by the expression of distinct transcription fac-
tors, cytokine production and immunological function. Th1 cells
express the transcription factor Tbet, produce IFN-γ and protect
from intracellular pathogens; Th2 cells express GATA-3, produce
IL-4, IL-5, IL-13 and protect from extracellular parasites; Th17
cells express ROR-γt, produce IL-17A and IL-17F and protect from
extracellular bacteria and fungi [1–3]. Although original studies
considered these phenotypes as mutually exclusive, it has been
described that competing effector programs can coexist within
the same cell [4–7]. Indeed, cells with a mixed phenotype can
originate directly from a na¨ıve precursor [8], as well as from the
polarization of mature cells which retain a certain degree of plas-
ticity, if exposed to appropriate cytokine stimulation. With this
regard, we and others have shown the existence of cells simul-
taneously producing both IL-17 and IFN-γ, named Th17/Th1, as
well as both IL-17 and IL-4, named Th17/Th2 [6, 9, 10].Moreover,
we have shown that both Th17 and Th17/Th1 cells can rapidly
acquire a full Th1 phenotype when exposed to the activity of pro-
inflammatory cytokines IL-12 or TNF-α [11, 12]. Human Th1 cells
originated from the phenotype shift of Th17 and Th17/Th1 cells
were defined as non-classic Th1, to distinguish them from classic
Th1 that instead were generated directly from the polarization
of na¨ıve cells [13]. Similar findings confirming the plasticity of
the Th17 phenotype were reported also in mouse [14, 15]. Epi-
genetic analysis has further reinforced the idea that non-classic
Th1 and classic Th1 cells are distinct lineages, since the former
show complete demethylation of RORC2 (encoding ROR-γt) and
hypomethylation of IL17A. Instead, both gene loci are hyperme-
thylated in the latter cell subset [16]. Human Th17 cells origi-
nate from a subset of CD4+CD161+ umbilical cord blood (UCB)
na¨ıve cells and are comprised within the CD4+CD161+CCR6+
subset of both circulating and infiltrating inflammatory cells in
adults [17]. Moreover, non-classic Th1 cells retain the expression
of both CD161 and CCR6, as well as the Th17 cells’ master tran-
scription factor ROR-γt [13]. Non-classic Th1 cells are enriched
at sites of inflammation [18], and it has been shown that such
a Th17 to Th1 phenotype transition is fundamental for disease
establishment in mouse models of diabetes [19] and inflamma-
tory bowel diseases [20]. Although the route of polarization from
Th17 to Th1 is widely accepted, it is not resolved whether Th1
can be polarized to Th17 cells. Moreover, to our knowledge, no
data have been published regarding the ability of the two subsets
of Th1 cell, classic and non-classic, to acquire IL-17 production.
In general, Th1 cells are thought to be phenotypically stable, and
less capable to acquire features of other cell subsets [21].
In this study we analyzed whether non-classic Th1 cells are ter-
minally differentiated, and thus phenotypically stable, or instead
they might be reverted toward Th17 in the appropriate microenvi-
ronment. Our findings show that non-classic Th1 cells are refrac-
tory toward common cytokine cocktails known to favor Th17 cell
development. By transcriptome analysis, we found that the tran-
scription factor Eomesodermin (Eomes) is expressed by classic
and non-classic Th1 cells in humans. Eomes expression has been
reported in NK and CD8 T cells, where it promotes IFN-γ, per-
forin and granzyme production [22, 23]. However, there is less
information regarding its role in CD4 T cells, mostly confined to
mouse experiments. Eomes expression seems to be dependent on
TCR and IL-2 signaling [24, 25]. Moreover, murine na¨ıve cells
express Eomes to favor the Th1 rather than the Th17 polarization
route [26, 27]. It has been reported that human memory CD4+
T cells exhibit higher Eomes expression than na¨ıve cells [28],
however the role of this transcription factor in humans is yet to be
defined. Our data show that Eomes is expressed by human non-
classic Th1 cells and it is involved in their phenotype development
from Th17 cells, favoring IFN-γ secretion, and their phenotypic
stability, preventing the re-expression of RORC2 and IL17A. These
in vitro data were confirmed also in vivo in a mouse model of
colitis. Moreover, we found that Eomes favors the acquisition of
pathogenic potential by T cells. Indeed, Eomes exacerbated signs
of inflammation during colitis in mice, and favored the develop-
ment of a cytotoxic signature in humans. Finally, we found that
Eomes drives the development of human IFN-γ+GM-CSF+ cells
in vitro. Moreover, IFN-γ+GM-CSF+ cells were found to accumu-
late in the synovial fluid of inflamed joints of patients affected by
juvenile idiopathic arthritis (JIA).
Results
Th17-derived (non-classic) Th1 cells are
phenotypically stable
We performed transcriptome analysis on a group of Th17, non-
classic Th1 and classic Th1 cell clones. Th17 and non-classic Th1
cell clones were generated from the CD161+CCR6+ fraction of
circulating CD4+ T cells obtained from healthy subjects. Classic
Th1 cell clones instead were obtained from the CD161−CCR6−
counterpart as already described [13]. The phenotype of all the
clones used in this study is reported in Supporting Information
Fig. 1. Cells were analyzed either resting or after activation with
anti-CD2 -CD3 -CD28-coated beads. Clustering-assisted heatmap
analysis showed that non-classic Th1 cells exhibit an intermediate
gene expression profile, when compared to Th17 and classic Th1
cells, sharing the expression pattern of several genes with Th17
cells and of several others with classic Th1 cells. This intermediate
behavior was more evident upon cell activation (Fig. 1A). This
observation was confirmed also by Principal Component Analysis
of the same transcriptome data, which showed that both resting
and activated non-classic Th1 cells cluster between Th17 and clas-
sic Th1 cells (Fig. 1B). To investigate whether non-classic Th1 cells
might revert toward the Th17 phenotype under Th17-promoting
conditions, we activated in vitro for one or two weeks pure non-
classic Th1 clones with anti-CD2 -CD3 -CD28 coated beads in the
presence of IL-1β and IL-23, able to drive Th17 polarization in
humans [17], or of IL-1β, IL-23, IL-6 and TGF-β [29]. As shown
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Figure 1. Non-classic Th1 cells are
phenotypically stable and cannot be
reverted toward Th17 in vitro (A) Hierar-
chical clustering-assisted heatmap per-
formed on the top 100 most variable
probes obtained from resting (left) or
anti-CD2, anti-CD3, anti-CD28 stimu-
lated (right) Th17 (blue), non-classic Th1
(green) and classic Th1 (red) cell clones.
5 distinct T cell clones for each phe-
notype were analyzed either resting or
antiCD2/3/28 stimulated. 5 independent
experiments were performed. Expres-
sion levels vary from red (low) to white
(high). (B) Principal component analy-
sis performed on transcriptome data
from 5 Th17, 5 classic Th1 and 4 non-
classic Th1 cell clones as in A. Empty
dots refer to resting cells, filled dots to
activated cells. (C) Non-classic Th1 cell
clones were stimulated with anti-CD2,
anti-CD3, anti-CD28 coated beads for
one or two weeks in the presence of the
indicated cytokine cocktails and then
restimulated with PMA plus Ionomycin
for flow cytometric cytokine expression
evaluation. 3 independent experiments
were performed on 3 different T cell
clones. One representative experiment
is shown. (D) Ex vivo sorted non-classic
Th1 cells were cultured for 1 week and
then reassessed for cytokine production
as in (C). One representative experiment
out of two independent experiments
performed is shown. (E) DNA methyla-
tion analysis was performed at RORC2,
IL17A, IL17F, IFNG, TBX21 gene loci at
the indicated CpG positions. DNA from
3 non-classic Th1 cell clones cultured
in vitro in the presence of the indicated
cytokine cocktails was pooled and then
analyzed by pyrosequencing. Methyla-
tion levels are represented with a col-
orimetric representation ranging from
yellow (0% of methylation) to red (100%
of methylation).
in Fig. 1C, non-classic Th1 cells did not acquire the ability to
produce IL-17 in any experimental condition. Moreover, ROR-γt
mRNA levels were only slightly increased (data not shown). Since
T cell cloning requires repetitive rounds of cell stimulation for
long periods, this may lead to excessive cell senescence and ter-
minal differentiation, thus reducing the cell plasticity potential.
Thus, we performed the same experiment also on freshly ex vivo
derived non-classic Th1 cells from peripheral blood of healthy
donors. IFN-γ producing cells were isolated by using a combina-
tion of surface markers (CD4+CD161+CCR6+) and cytokine secre-
tion assay. Also directly ex vivo isolated non-classic Th1 cells were
completely refractory to Th17-polarizing cytokines (Fig. 1D). To
analyze whether the treatment with Th17-promoting cytokines
induced any change in non-classic Th1 cells at epigenetic level,
we investigated the DNA methylation pattern at cytokine and
transcription factor gene loci. Non-classic Th1 cells exhibited full
demethylation of RORC2, hypomethylation of IL17A and IL17F,
reduced methylation levels of TBX21 (encoding Tbet) and low
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methylation at the IFNG locus (Fig. 1E). Following cytokine treat-
ment (i.e. IL-1β plus IL-23 or IL-1β plus IL-23 plus IL-6 plus TGF-β)
no changes in the methylation pattern at these loci were observed
(Fig. 1E). These data show that non-classic Th1 cells have a stable
phenotype that is not affected by external cytokine stimulation.
Forced expression of ROR-γt partially restores IL-17
production by non-classic Th1 cells
ROR-γt is the master transcription factor of Th17 cells, and it
is fundamental for the expression of the typical Th17 transcrip-
tional signature [30]. Quantifying RORC2 mRNA levels on Th17,
non-classic Th1 and classic Th1 cell clones (Fig. 2A), as well as
on ex vivo sorted T-cell subsets (Fig. 2B), non-classic Th1 cells
expressed significantly reduced levels compared to Th17, but sig-
nificantly higher than classic Th1 cells. Thus, we hypothesized that
residual ROR-γt levels in non-classic Th1 cells may be insufficient
to trigger IL17A expression. Using lentiviral vectors, we ectopi-
cally overexpressed RORC2 in non-classic Th1 and, as a control, in
classic Th1 cell clones, characterized by IFN-γ expression by vir-
tually all cells and absence of IL-17 expressing cells. RORC2 levels
were comparable between the two populations upon transduction
(data not shown). RORC2 overexpression alone, in the absence
of any exogenous cytokines, led to a significant increase in the
percentage of IL-17 producing cells only in the non-classic Th1
cell subset (Fig. 2C and D). We repeated the same experiment
also on freshly ex vivo-recovered non-classic Th1 and classic Th1
cells, sorted according to CD3+CD4+CD161+CCR6+CXCR3+ and
CD3+CD4+CD161−CCR6−CXCR3+, respectively [31], to avoid
the strong ex vivo restimulation required for the cytokine secretion
assay. Although by this sorting strategy the enriched non-classic
Th1 cell population included IL-17 expressing Th cells, ectopic
RORC2 overexpression resulted in a major increase in IL-17 pro-
ducing cells in the non-classic Th1 compared to the classic Th1
subset (Fig. 2E). The increased production of IL-17 by non-classic
Th1 cells was confirmed also onmRNA level (data not shown). Col-
lectively, these data support the concept that upon proper ROR-γt
expression both classic and non-classic Th1 cells can start produc-
ing IL-17, but non-classic Th1 can be more easily phenotypically
redirected. However, the finding that IL-17 production can be
observed only upon ectopic expression of ROR- γt, while com-
mon pro-Th17 cytokine cocktails are ineffective, suggests that a
molecular machinery aimed to guarantee cell phenotype stability
is active in Th1 cells.
Both non-classic and classic Th1 cells express high
levels of Eomes
To identify the molecular machinery possibly involved in the
inhibition of the Th17 program in Th1 cells, we analyzed
the transcriptomes of Th17, non-classic and classic Th1 cell
clones. Bioinformatic analysis allowed to compare differentially
expressed genes within the three T cell subsets (Fig. 3A). As
expected, RORC2, CCR6, KLRB1, IL23R, IL1R1, RORA were among
the genes selectively expressed at lower levels by classic Th1
when compared to both non-classic Th1 and Th17 cells. Instead,
classic Th1 displayed significantly higher IFNG expression when
compared to Th17 cells. The transcription factor Eomes was
among the 153 genes highly expressed by both non-classic Th1
and classic Th1 compared to Th17 cells. Quantitative Real-Time
PCR on Th cell clones confirmed the selective higher Eomes
mRNA levels in both non-classic Th1 and classic Th1 compared to
Th17 and Th17/Th1 cells (Supporting Information Fig. 2). TCR
activation did not affect Eomes mRNA expression (Supporting
Information Fig. 2). Also freshly ex vivo sorted classic and
non-classic Th1 cells expressed higher Eomes mRNA compared
to Th17 cells (Fig. 3B). Similar findings were obtained also on
protein level by confocal microscopy (Fig. 3C).
IL-2 and IL-12 cooperate to initiate Eomes transcription
IL-12 is themost potent cytokine able to polarize human Th17 cells
toward the non-classic Th1 phenotype [11]. To analyze whether
IL-12 can regulate Eomes expression, we activated Th17 cell clones
in vitro with allogenic feeder cells and IL-2, in the presence or in
the absence of exogenous IL-12. As shown in Fig. 4A, the addition
in culture of IL-12 significantly upregulated Eomes levels.
It has also been proposed that Eomes transcription may be
favored by IL-2 signaling itself [25] via a STAT5B-dependent
pathway [32]. We have shown that IL-2 signaling is significantly
impaired in Th17 cells, due to the activity of the transcription
factor Musculin, which targets the STAT5B pathway [31]. Thus,
we hypothesized that Musculin may be indirectly involved in
preventing Eomes expression in Th17 cells. Indeed, Musculin
is commonly downregulated during the non-classic Th1 cell
development, thus restoring proper IL-2 sensitiveness [31]. In
concordance, our transcriptome data show that MSC (encoding
for Musculin) is one of the genes that are expressed, from high
to low levels, in Th17, non-classic Th1 and finally classic Th1
cells (Fig. 3A). In line with this finding, we observed a negative
correlation between Eomes and MSC mRNA expression levels
in Th cell clones (Fig. 4B). To provide additional proof of the
importance of the IL-2 signaling in controlling Eomes transcrip-
tion, we ectopically overexpressed Musculin via lentiviral vector
in non-classic Th1 cell lines and monitored Eomes mRNA levels.
No significant changes in Eomes expression were observed (data
not shown), suggesting that IL-2 signaling is not involved in the
maintenance, but rather in the de novo induction of Eomes expres-
sion. To test this, we decided to reproduce in vitro the non-classic
Th1 cell development by exposing Th17 cells to exogenous IL-12.
To prevent the physiological downregulation of Musculin during
the phenotype shift from Th17 to non-classic Th1, we decided to
overexpress Musculin in Th17 cells via lentiviral approach. Cells
were then stimulated in vitro with IL-12 to favor their phenotype
shift toward Th1. The data showed that Th17 cells overexpressing
Musculin, thus exhibiting reduced IL-2 sensitiveness, displayed
a significant reduction in Eomes mRNA transcription (Fig. 4C).
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Figure 2. ROR-γt levels are critical to allow IL-17 re-expression by non-classic Th1 cells (A) RORC2mRNA levels were evaluated by qPCR on 20 T cell
clones for each of the indicated phenotypes and normalized on cell number. T cell clones of all the phenotypes were obtained from three different
donors in different experiments and frozen for mRNA expression studies. Data are presented as mean+SE and are pooled from three independent
experiments. **p<0.01; ***p<0.001 using Student’s t-test. (B). RORC2 mRNA levels were evaluated by qPCR on the indicated T cell subsets freshly
sorted ex vivo from PB of three different donors in three independent experiments and normalized on cell number. Data are presented as mean
+SE and and are pooled from three independent experiments**p<0.01; ***p<0.001 using Student’s t-test. (C) Non-classic Th1 and (D) classic Th1
cell clones were transduced with control- or RORC2-expressing lentiviral vectors, cultured for two weeks and then assessed by flow cytometry
for cytokine production upon PMA plus Ionomycin stimulation. Three independent experiments were performed on 3 distinct non-classic and 3
distinct classic-Th1 clones. Mean percentages of cytokine producing cells from three independent experiments +SE are depicted and are pooled
from three independent experiments. *p < 0.05 using Student’s t-test. (E) Freshly ex vivo sorted non-classic (CD3+CD4+CD161+CCR6+CXCR3+) and
classic (CD3+CD4+CD161−CCR6−CXCR3+) Th1 cells obtained from PB of one donor were transduced in vitro in one single experiment with control-
or RORC2-expressing lentivirus, cultured for 2 weeks and then assessed by flow cytometry for cytokine production upon PMA plus Ionomycin
stimulation. The difference in the percentage of IL-17 producing cells between RORC2- and control-vector transduced cells (IL17) for both cell
subsets is indicated.
Altogether, these data support the concept that IL-2 and IL-12
combined activity is critical to ensure proper Eomes transcription.
Eomes can repress RORC2 and IL17A in Th17 cells
By quantitative Real-Time PCR on several Th cell clones, we
observed a negative correlation between RORC2 and Eomes (Sup-
porting Information Fig. 3A) as well as between IL17A and Eomes
(Supporting Information Fig. 3B). Moreover, single cell analysis
of expression of Eomes, IFN-γ and IL-17 by flow cytometry by
peripheral blood CD4+ T cells from healthy donors (Supporting
Information Fig. 3C) as well as CD4+ T cells from the synovial
fluid of JIA patients (Supporting Information Fig. 3D) confirmed
that Eomes positive cells were contained within the IFN-γ+ cell
subset but not within IL-17+ cells.
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Figure 3. Eomes is selectively expressed by both subsets of Th1 cells (A) Comparison of differential expression analysis of transcriptome data
from Th17, non-classic and classic-Th1 clones. The green circle contains differentially expressed genes between classic Th1 and Th17; the blue
circle contains differentially expressed genes between non-classic and Th17; the red circle contains differentially expressed genes between non-
classic and classic Th1. Size of the circle is proportional to the total amount of differentially expressed genes. Red numbers and names represent
upregulated genes; blue numbers and names represent downregulated genes. (B) Eomes mRNA levels were evaluated by qPCR on the indicated
T cell subsets freshly sorted from six different donors in six independent experiments and normalized on cell number. Data are presented asmean
+SE and are pooled from six independent experiments. *p<0.05 using Student’s t-test. (C) Confocal microscopy analysis of Eomes expression (red)
by Th17, non-classic and classic Th1 cell clones. Cell membranes were identified by CD3 staining (green) while nuclei were stained with TOPRO
dye (blue). Image of one representative clone out of 3 evaluated for each phenotype in 3 independent experiments is shown. Scale bar, 5 μm. On
the right, mean fluorescence intensity of Eomes expression pooled from three different experiments +SE ***p<0.001 using Student’s t-test.
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Figure 4. IL-2 and IL-12 cooperate for Eomes transcription initiation (A) EomesmRNA levels were evaluated by qPCR in Th17 cell clones stimulated
in vitro with allogenic feeder cells and IL-2, with or without exogenous IL-12 as indicated. 4 independent experiments on 4 different clones were
performed. Normalization was performed on cell number. Data are presented as mean +SE and are pooled from four independent experiments.
*p<0.05. (B) Pearson’s correlation between Eomes and MSC mRNA levels evaluated by qPCR in 28 T helper cell clones calculated. T cell clones from
three different donors were frozen for mRNA evaluation in different experiments. (C) PB-sorted Th17 cell lines untransduced or transduced with
control- or Musculin-expressing lentiviral vector were stimulated with exogenous IL-2 and IL-12 for twoweeks and then evaluated for EomesmRNA
expression by qPCR. Cells were collected from three donors and transduced in three independent experiments. Normalization was performed on
cell number. Pooled data are presented as mean +SE. *p<0.05 using Student’s t-test.
To understand the biological role of Eomes in differentiated
human Th cells, we analyzed the transcriptomes in Th17 cells
ectopically overexpressing Eomes. As shown in Supporting
Information Fig. 3, forced expression of Eomes induced a
significant alteration in the gene expression profile, reminiscent
of a Th1 signature. Of note, genes encoding for cytotoxic
molecules such as perforin and granzymes were upregulated in
Eomes-overexpressing cells (Fig. 5A and Supporting Information
Fig. 4). In parallel, genes associated to the Th17 phenotype were
repressed (Fig. 5A). By Real-Time qPCR we confirmed significant
EomesmRNA levels only in Eomes-vector transduced cells, if com-
pared to untransduced or control-vector transduced cells (Fig. 5B).
In parallel, we noticed in Eomes-overexpressing cells a significant
reduction in RORC2 (Fig. 5C) and IL17A (Fig. 5D) mRNA levels,
together with an increase in those of IFNG (Fig. 5E). Flow
cytometric analysis revealed that Eomes-vector transduced subset
exhibited a significant reduction in the percentage of IL-17 single
producing cells. In parallel, we observed an increase in the percent-
age of cells producing IFN-γ alone and of cells producing neither
IL-17, nor IFN-γ (Fig. 5F). After one month of in vitro culture,
Eomes vector-transduced cells had lost almost entirely the capac-
ity to secrete IL-17, while untransduced cells or control-vector
transduced cells had maintained the original Th17 phenotype
(Fig. 5G). Altogether these data confirm that Eomes can selectively
repress the expression of Th17 associated genes, and favor that
of IFNG, thus stabilizing the Th1 phenotype. Finally, chromatin
immunoprecipitation experiments performed with an anti-Eomes
antibody on Eomes-overexpressing Th17 cells, showed that Eomes
binds directly to RORC2 and IL17A to regulate their expression
(Fig. 5H).
Eomes controls the expression of RORC2 and IL17 also
in an inflammatory setting in vivo
To confirm the role of Eomes in controlling the expression of
Th17 associated genes in mature effector T cells also in vivo, we
isolated na¨ıve T cells from Eomesfl/flxRosa26:CreERT2 mice and
we activated them in vitro in the presence of IL-6, IL-23 and TGF-β
to obtain Th17 cells (Supporting Information Fig. 6A). Despite a
subset of cells were not producing IL-17 upon PMA/Ionomycin res-
timulation, Th17 skewing was supported by homogenous ROR-γt
expression and contemporary absence of IFN-γ and Tbet (Support-
ing Information Fig. 6B). Polarized cells were then transferred into
recipient Rag1−/− mice to induce T cell-dependent colitis. Pre-
vious studies have already demonstrated that transferred Th17
cells polarize toward Th1 in vivo, and only after this conver-
sion they acquire full pathogenicity [20]. Directly after Th17 cell
transfer and for the following 4 days, recipient mice were treated
with vehicle or Tamoxifen to induce Eomes knockdown. With this
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Figure 5. Eomes contributes to non-
classic Th1 cell phenotype maintenance
by inhibiting the expression of RORC2 and
IL17A and favoring that of IFNG (A) Hierar-
chical clustering-assisted heatmap analy-
sis on selected genes from transcriptome
data of control-vector or Eomes-vector
transduced Th17 cells. One Th17 cell
line was transduced either with control-
or Eomes-vector. Two technical repli-
cates for each subset are shown. Cells
were collected in a single experiment.
Expression levels vary from red (low) to
white (high). Untransduced, control- or
Eomes-vector transduced Th17 cell lines
were evaluated for Eomes (B), RORC2 (C),
IL17A (D) and IFNG (E) mRNA expression
by qPCR after anti-CD2+anti-CD3+anti-
CD28 stimulation. Normalizationwas per-
formed on cell number. Six indepen-
dent experiments on cells collected from
six different donors were performed.
Pooled data are presented as mean +SE.
*p<0.05 using Student’s t-test. (F) Untrans-
duced, control- or Eomes-vector trans-
duced Th17 cell lines were evaluated by
flow cytometry for IL-17 and IFN-γ pro-
duction upon PMA plus Ionomycin stimu-
lation. Six independent experiments were
performed. Pooled data are presented as
mean +SE. *p < 0.05; **p < 0.01 using
Student’s t-test. (G) Representative plot
of cytokines production from one exper-
iment in (F) 2 or 4 weeks after infection.
(H) Chromatin Immunoprecipitation was
performed with an anti-Eomes antibody
on Eomes-vector transduced Th17 cells
followed by qPCR amplification of RORC2,
IL17A and IL2 genes. Pooled data from
four independent experiments are pre-
sented as fold enrichment of immunopre-
cipitated DNA over the negative control,
+SE. *p < 0.05 using Student’s t-test.
experimental setting we aimed to understand if Eomes plays a role
in Th1 cell development from Th17 also in vivo, and if it has a
role in the acquisition of the pathogenic potential of Th1 cells in
colitis. Colitis progression was comparable over time between the
two groups, as confirmed by the body weight-loss curves (Fig. 6A).
However, Eomes ablation by Tamoxifen treatment significantly
reduced absolute numbers of colon-infiltrating T cells, suggest-
ing reduced inflammation (Fig. 6B). Of note, this was not due
to a toxic effect of the drug, since a higher percentage of Ki-67+
CD4+ T cells was observed ex vivo in the group of Tamoxifen-
treated mice when compared to the control group (Supporting
Information Fig. 6E). These data were confirmed by a reduced
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Figure 6. Eomes controls non-classic Th1 phenotype development also in an inflammatory disease setting in vivo (A) Weight loss curve of colitic
RAG-1−/− mice after intravenous injection of in vitro differentiated Th17 Eomesfl/flxRosa26:CreERT2 cells. Arrows indicate tamoxifen or vehicle
injections. (B) Absolute cell numbers of CD3+CD4+ T lymphocytes in colon and spleen of colitic RAG-1−/- mice that received tamoxifen or vehicle,
21 days after T cell transfer. (C) Weight-to-Length ratio expressed as mg/cm of colons isolated from colitic RAG-1−/− mice that received tamoxifen
or vehicle, 21 days after T cell transfer. (D) Frequency of Eomes+ cells among CD3+CD4+ T lymphocytes in colon and spleen of colitic RAG-1−/−
mice that received tamoxifen or vehicle, 21 days after T cell transfer (E) Frequency of ROR-γt+ cells among CD3+CD4+ T lymphocytes in colon
and spleen of colitic RAG-1−/− mice that received tamoxifen or vehicle, 21 days after T cell transfer. (F) Representative FACS-plot of Eomes versus
ROR-γt expression among CD3+CD4+ T lymphocytes in vehicle- or Tamoxifen-treated mice. Frequency of IL-17+IFN-γ− (G), IL-17+IFN-γ+ (H) or
IL-17−IFN-γ+ (I) cells among CD3+CD4+ T lymphocytes upon PMA/Ionomicin re-stimulation in colon and spleen of colitic RAG-1−/− mice that
received tamoxifen or vehicle, 21 days after T cell transfer. (J) Representative FACS-plot of IL-17 vs IFN-γ expression among CD3+CD4+ T lympho-
cytes in vehicle- or Tamoxifen-treated mice. Data in (A) are representative of two independent experiments, each with 5 to 6 mice per group. Data
in (B) - (J) represent two pooled experiments, each with 5 to 6 mice per group. Data are shown as mean ± SEM. * = p  0.05, as determined by
unpaired t-test with Welch´s correction or Mann–Whitney.
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weight to length ratio of colons in colitic mice upon Eomes dele-
tion (Fig. 6C). Moreover, histological analysis showed a reduced
submucosal infiltration, despite all the other parameters were not
different among the two groups (Supporting Information Figs. 6C
and 6D). Colon- and spleen-infiltrating lymphocytes of Tamoxifen-
treated mice exhibited a marked reduction of Eomes expression
(6D). Strikingly, we observed a significant enrichment of ROR-γt+
cells, both in the colon and the spleen of Tamoxifen-treated mice
as compared to vehicle-treated group (Fig. 6E). In line with this,
the frequency of total IL-17 producing cells in Tamoxifen-treated
group was increased in the colon, with a similar trend also in the
spleen, compared to the control group. Of note, this difference was
not due to an enrichment of IL-17+IFN- γ− but of IL-17+IFN- γ+
cells in Eomes-ablated mice (Fig. 6G-H). The IL-17−IFN-γ+ sub-
set was not affected by Eomes deficiency (Fig. 6I). All toghether
these data suggest that Eomes is primarily involved in the inhi-
bition of the expression of Th17 associated-genes rather than in
the initial IFN-γ production. In agreement, previous observations
have shown that several redundant molecular pathways which are
involved in IFNG gene expression do exist [24]. Finally, myeloid
cell compartment was not affected by Eomes deletion during coli-
tis (Supporting Information Figs. 6F, 6G, 6H, 6I). Altogether, these
data confirm that Eomes represses IL-17 and ROR-γt expression
also in vivo and confers proinflammatory features to Th1 cells.
Eomes drives the generation GM-CSF+IFN-γ+ cells that
are enriched in the joints of JIA patients
It has been reported that Eomes may favor the development of
pathogenic GM-CSF+IFN-γ+ cells in the mouse model of multiple
sclerosis [33]. Indeed, we observed a positive correlation between
Eomes and GM-CSFmRNA levels in Th cell lines (Fig. 7A). Accord-
ingly, we found significantly higher GM-CSF levels in both non-
classic and classic Th1 cells, if compared to Th17, both at mRNA
(Fig. 7B) and protein level in culture supernatants (Fig. 7C).
Finally, we observed a significant increase in GM-CSFmRNA levels
in Th17 cells upon Eomes transduction (Fig. 7D), thus confirming
that Eomes is involved in GM-CSF secretion by Th cells. Chro-
matin immunoprecipitation experiments performed on Eomes-
overexpressing Th17 cells failed to demonstrate direct binding
of Eomes on CSF2 gene, in agreement with published data in
mouse [33], suggesting that Eomes indirectly favors GM-CSF pro-
duction. To verify whether pathogenic GM-CSF+IFNγ+ cells are
present at sites of inflammation in humans, we enrolled four JIA
patients and we analyzed Eomes, IFNγ and GM-CSF expression in
peripheral blood and synovial fluid-infiltrating cells. Simultaneous
staining of Eomes and GM-CSF was not technically possible due to
the harsh fixation procedure required for transcription factor anal-
ysis which presumably alters the antibody-specific epitope of the
GM-CSF protein. However, we observed a significant enrichment
of both Eomes+IFNγ+ and GM-CSF+IFNγ+ cells in the synovial
fluid than in PB confirming the possible involvement of these cell
subsets in disease induction and maintenance (Fig. 7E and F).
Discussion
T cell plasticity is a matter of debate, since the concept of “cell
polarization”, previously attributed only to na¨ıve uncommitted
cells, has more recently been extended to mature effector cells
as a consequence of microenvironmental changes. Th17 cells are
the most meaningful example of plasticity since these cells can be
easily induced to acquire the ability to produce both IFN-γ and
IL-4 if exposed to appropriate stimulation [34]. This is a widely
accepted concept, since there are several data, both at cellular and
epigenetic level, supporting it both in humans and mice [11, 14,
15, 18, 35]. By contrast, Th1 cells are commonly thought to be
more phenotypically stable. However, a report by Liu et al [36]
suggests that Th1 cells from mice possessing a transgenic TCR
specific for the microbiota antigen CBir1 flagellin may acquire the
ability to produce IL-17 in the gut upon injection in Rag1−/− mice.
It must be noted that all the experimental data were generated
using in vitro polarized cells, thus arising some concerns regarding
the phenotype stability of the cells before their transfer.
In the studies reported so far, to our knowledge, nobody has
considered the existence of two distinct subsets of Th1 cells, classic
and non-classic, which may exhibit different plasticity toward the
Th17 phenotype. By contrast, our data support the idea that, at
least in humans, these two Th1 subsets may really exhibit different
plasticity. Indeed, we show here that non-classic Th1 cells display
an intermediate gene expression profile between Th17 and classic
Th1 cells. Moreover, our previous observation showed a similar
behavior also at epigenetic level. Non-classic Th1 cells display
hypomethylation at both RORC2 and IL17A, that instead are fully
methylated in classic Th1 cells [16]. Here we further investigated
the molecular mechanisms that control the generation of non-
classic Th1 from Th17 cells, and we provided more convincing
evidence regarding the possibility of the opposite plasticity, i.e.
the capacity of Th1 cells to acquire IL-17 production.
We demonstrated that, despite the similarities with the Th17
subset, non-classic Th1 cells cannot be induced to produce IL-17
if cultured in presence of Th17-polarizing cytokines. This is at
least partially due to their reduced ROR-γt levels. Indeed, RORC2
forced expression allowed non-classic Th1 cells to restore IL-17
production. Of note, with this experimental approachwewere able
to induce de novo IL-17 expression also by classic Th1 cells, despite
at lower levels than by non-classic Th1. These findings suggest
the possibility that certain microenvironmental conditions capable
of promoting high ROR-γt expression may be able to drive the
polarization of Th1 cells toward Th17. This scenario is presently
unknown and will require additional investigations.
We also found here that a molecular machinery dependent
on the transcription factor Eomes is activated in Th1 cells and
is responsible for their phenotype development and maintenance.
The role of the transcription factor Eomes in CD4+ T cells has been
underestimated so far, mainly because of its lower expression lev-
els compared to CD8+ T cells. Moreover, most of the functional
data in the literature are confined to the mouse setting, with a
profound lack of information regarding its role in humans. Our
present findings show that Eomes favors the phenotype shift of
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Figure 7. Eomes expressing cells display high GM-CSF levels and are enriched in the SF of JIA patients (A) Pearson’s correlation between GMCSF
and Eomes mRNA levels evaluated by qPCR on nine T cell lines obtained from three donors in independent experiments. (B) GMCSF mRNA levels
were evaluated on 7 Th17, 7 non-classic and 7 classic Th1 clones in 7 independent experiments. Pooled data are presented as mean +SE. **p < 0.01.
(C) GM-CSF protein levels were evaluated in the supernatants of 6 Th17, 6 non-classic and 6 classic-Th1 cell clones in 6 independent experiments.
Pooled data are presented as mean +SE. *p < 0.05 using Student’s t-test. (D) GMCSF mRNA levels were evaluated on untransduced, control- or
Eomes-vector transduced Th17 cells. Data are pooled from four independent experiments (same as in 5B-E) +SE. *p < 0.05 using Student’s t-test.
(E) The frequency of Eomes+IFN-γ+ CD4 T cells in the PB and SF of JIA patients was evaluated by flow cytometry. Data are presented as mean +SE
pooled from four patients. *p < 0.05 using Student’s t-test. (F) The frequency of GM-CSF+IFN-γ+ CD4 T cells in the PB and SF of JIA patients was
evaluated by flow cytometry. Data are presented as mean +SE pooled from four patients. *p < 0.05 using Student’s t-test.
Th17 cells toward non-classic Th1 by both reinforcing IFN-γ pro-
duction and inhibiting the expression of RORC2 and IL17A genes.
In agreement with these data non-classic Th1 cells, expressing
high levels of Eomes, display significantly reduced ROR-γt levels
than Th17 cells and complete absence of IL-17 secretion.
It has previously been reported that inhibition of Eomes gene
expression via a TGF-β-mediated mechanism during murine na¨ıve
T cell polarization toward Th17 is fundamental to achieve proper
ROR-γt and IL-17 expression [27]. Our data show that Eomes is
critical to inhibit the Th17 program also in mature effector cells.
This is of importance because Tbet, the master Th1 transcription
factor, seems to lack such an inhibitory effect on RORC2 and IL17A
since it is expressed at discrete levels by both human Th17 and
Th17/Th1 cells [11]. Moreover, Th17/Th1 cells display absence
of Eomes expression, which suggests that several other mecha-
nisms are involved in the first wave of IFN-γ production, while
its activity seems to be crucial for the inhibition of typical Th17
genes. Of note, in the accompanying paper by Gruarin et al., the
authors show that also in human Tr1 cells Eomes is critical to
inhibit the expression of RORC and Th17-associated cytokines,
while promoting IFN-γ.
In agreement with findings on human cells, we also show
that even in mice Eomes can regulate the development of Th1
from Th17 cells. Indeed, upon transfer of Th17 cells in recipient
Rag1−/− mice, which leads to T cell phenotype shift toward Th1
and colitis development, we observed higher frequencies of IL-
17 and ROR-γt positive cells both in the colon and the spleen in
the Eomes–deficient group. Although a subset of the cells was not
producing IL-17 upon PMA-Ionomycin stimulation prior transfer,
the entire population exhibited ROR-γt expression, thus suggest-
ing their Th17-skewing. In this experiment we also noted reduced
signs of colon inflammation, as suggested by reduced weight to
length ratio when compared to control mice. In agreement with
this, we observed a significant reduction of total CD4+ T cells than
the control group, despite comparable numbers in the spleen. This
effect was not related to a drug-related toxic effect, since CD4+
cells from Tamoxifen-trated mice displayed even a higher per-
centage of Ki-67 expression than the control group. This data was
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confirmed also by histological analysis, which showed a reduced
submucosal infiltrate in mice with Eomes deficient T cells. Thus,
Eomes is involved in the acquisition of a proinflammatory poten-
tial by Th cells in colitis. These data open new possibilities for
further investigation, since Eomes may control not only the cell
phenotype but also cell proliferation, survival and/or recruitment
to inflamed tissues. Indeed, it is already known that Th1 cells dis-
play higher proliferation rate upon TCR stimulation if compared
to Th17 cells [37].
Another interesting observation of this study was that IL-2
and IL-12 cooperate for Eomes expression in Th17 cells. We have
shown already that IL-2 signaling is impaired in Th17 cells due to
the activity of the transcription factor Musculin, which selectively
dampens the STAT5B pathway. Moreover, Musculin is downregu-
lated by non-classic Th1 cells [31]. Here we found that Musculin
forced expression during non-classic Th1 development from Th17
cells significantly affects the induction of Eomes gene transcription.
In agreement with these observations, it has been demonstrated
that Eomes is a selective target of STAT5B downstream of IL-2 stim-
ulation [32]. Wemay speculate that the reduced IL-2 sensitiveness
of Th17 cells is important for a mechanism of cell phenotype pro-
tection and maintenance, aimed to keep high IL-17 levels via the
impairment of Eomes expression. Thus, proper IL-2 sensitiveness
must be achieved to shut down IL17A transcription. A negative
role for IL-2 signaling on IL-17 expression has already been pro-
posed, due to the STAT5 occupancy of the IL17A promoter, that
is no longer available for binding of the transcription-promoting
factor STAT3 [38]. Our finding that Eomes expression is prevented
in Th17 cells via the inhibition of the IL-2 pathway provides an
additional rationale for the documented inhibitory activity of IL-2
on the Th17 phenotype.
It has been proposed that Eomes may drive the development
of pathogenic Th1 cells in a mouse model of multiple sclerosis by
favoring the contemporary secretion of IFN-γ and GM-CSF [33].
Our data on human cells show that both classic and non-classic
Th1 cells secrete higher GM-CSF levels than Th17, and Eomes
is involved in this capacity as shown by its overexpression per-
formed in Th17 cells. In this study, we had also the possibility to
analyze cells from a human inflammatory setting, i.e. the synovial
fluid of JIA patients. A significant enrichment of both Eomes+IFN-
γ+ and IFN-γ+GM-CSF+ cells in the synovial fluid compared to
the peripheral blood was observed, thus confirming the possible
involvement of Eomes+-classic and Eomes+-non-classic Th1 cells
in disease initiation and progression. Thus, our findings are con-
sistent with previous data suggesting that Eomes can drive the
development of pathogenic cells [39]. In line with this, and with
our colitis experiments, our transcriptome data show that Th17
cells ectopically overexpressing Eomes acquire a cytotoxic poten-
tial via upregulating perforin and granzymes levels.
In conclusion, our findings indicate that the phenotype shift
from Th17 to Th1 is tightly controlled at molecular level. Eomes
plays a role in this scenario, by reinforcing IFN-γ production and
selectively inhibiting the expression of RORC2 and IL17A. This
concept is of particular importance for chronic inflammatory dis-
orders and autoimmunity. Indeed, there are now accumulating
evidences in the literature suggesting that Th17 cells acquire
higher pathogenicity after conversion to Th1 [19, 20, 40]. For
this reason, new therapeutic strategies for such chronic inflam-
matory disorders may be directed to prevent the conversion of
Th17 cells into Th1. In this view, some biological drugs acting
on factors known to favor this phenotype shift are already avail-
able. Indeed, the anti-p40 mAb Ustekinumab that contemporary
neutralizes both IL-12 and IL-23, may work preventing the Th1
conversion of Th17 cells [41]. On the other side, finding a way to
promote the reversion of non-classic Th1 cells toward Th17 may
also be beneficial. The results of the present study suggest that
this route is complex, and difficult to achieve, due to the existence
of a molecular machinery which includes the transcription factor
Eomes and that creates a lock to cell phenotype changes. In this
view, a recent study has shown the possibility to attenuate the
asthmatic response after allergen exposure in asthmatic patients
via using a new gene targeting approach which allowed to specif-
ically inhibit GATA3 expression [42]. For this reason, the iden-
tification of all the actors that collectively favor generation and
stabilization of Th1 cells from Th17 is crucial. Understanding the
molecular networks that stabilize the Th1 phenotype may suggest
the development of drugs to specifically target those molecules.
Materials and methods
Subjects
Peripheral Blood (PB) samples were obtained fromhealthy donors.
Synovial Fluid (SF) and paired PB samples were collected from JIA
patients. The procedures followed in the study were in accordance
with the ethical standards of the Regional Committee on Human
Experimentation.
Mice
RAG1−/− and Eomesfl/flxRosa26:CreERT2 mice were housed
and bred under SPF conditions. Before Th17 cell transfer
and colitis induction, RAG1−/− mice were tested for positiv-
ity to SFB and Helicobacter species (H. spp) via PCR on
fecal DNA with the following primer pairs: H. spp [For-
ward: 5’-ctatgacgggtatccggc-3’, Reverse: 5’-attccacctacctctccca-
3′]; SFB [Forward: 5′-gacgctgaggcatgagagcat-3’, Reverse: 5’-
gacggcacggattgttattca-3’]. Experiments were performed according
to institutional guidelines and German Federal laws on animal
protection.
Reagents
The medium used was RPMI 1640 (Seromed, Berlin, Germany),
supplemented with 2 mM L-glutamine, 1% nonessential amino
acids, 1% pyruvate, 2 × 10–5 M 2-mercaptoethanol (2-ME) (all
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from Gibco Laboratories, Grand Island, NY), and 10% FCS (Euro-
clone). Unlabelled or flurochrome-conjugated anti-CD3, CD4,
CD8, CD161, CCR6, CD271, IFN-γ, GM-CSF, isotype-matched
control mAbs were from BD Biosciences (Mountain View, CA).
Flurochrome-conjugated anti-IL-17 and anti-Eomes mAbs were
from eBiosciences (San Diego, CA). PE-Cy7-conjugated CD161
was from (Miltenyi Biotec, Bergisch Gladbach). Flurochrome-
conjugated anti-CXCR3mAbs were from R&D System. Phorbol 12-
myristate 13-acetate (PMA), ionomycin, brefeldin A and saponin
were from Sigma Aldrich Co. (St. Louis, MO). Recombinant human
IL-1β, IL-6, IL-12, IL-23, TGF-βwere purchased fromR&DSystems.
T cell recovery and expansion
Mononuclear cell (MNC) suspensions were obtained from PB and
SF by centrifugation on Ficoll-Hypaque gradient. PB CD4+ T cells
were negatively selected by high-gradient magnetic cell sorting
(Miltenyi Biotec), as previously described [17] and were then
further divided into CD161+ and CD161− by immunomagnetic
cell sorting. PB CD4+CD161+ and CD4+CD161− T cell popu-
lation were further subdivided in CCR6+ and CCR6− cell frac-
tions by FACSAria (BD Biosciences). PB CD4+CD161+CCR6+ and
CD4+CD161−CCR6− cell lines were then cultured under limiting
dilution (0.3 cell/well) in the presence of 105 irradiated (9000
rad) allogeneic PBMNCs as feeder cells, 1% PHA (vol/vol), and
50 U/mL rhIL-2 (Proleukin, Prometheus, Inc., San Diego, USA)
in order to obtain Th17, non-classic Th1 and classic Th1 clones
respectively. Recovered clones were classified by flow cytome-
try for intracellular staining of IL-17 or IFN-γ cytokines. Pro-
duction of cytokines by each clone was arbitrarily considered
as noteworthy when the proportion of producing T cell blasts
was < 20%. [11, 13]. PB CD4+CD161−CCR6− were also FACS
enriched for CXCR3 expression to obtain classic Th1 cell poly-
clonal population. PB CD4+CD161+CCR6+ were further divided
in CXCR3+ and CXCR3− by FACS to obtain non-classic Th1 and
Th17 polyclonal cell lines, respectively.
Cytokine secretion assay
PB CD4+ T cells were negatively selected by high-gradient mag-
netic cell sorting and further divided into CCR6+ and CCR6− cells
by immunomagnetic cell sorting, then were stained with anti-
CD161 PE-Cy7, stimulated with PMA-ionomycin, recovered after
3 and half hours, washed and then stained with IFN-γ and IL-17
catch reagents (Miltenyi Biotec), followingmanufacturer’s instruc-
tions. Following additional 45 min of incubation (37°C, 5% CO2)
cells were stained with anti-CD3-Pacific Blue, -IL-17-APC and -
IFN-γ-FITC, analyzed and sorted by FACSAria in order to collect
CD4+CCR6+CD161+ IL-17−IFN-γ+ T cells.
In vitro T cell stimulation with exogenous cytokines
Non-classic Th1 cells, either T cell clones or freshly ex vivo sorted,
were stimulated with anti-CD2, anti-CD3, anti-CD28 coated beads
(Miltenyi) in the absence or in presence of recombinant IL-1β (10
ng/mL), IL-6 (2 ng/mL), IL-23 (20 ng/mL), TGF-β (5 ng/mL)
(all from R&D Systems) for one or two weeks. Following, cells
were harvested and restimulated in vitro with PMA (10 ng/mL)
and Ionomycin (1 μM) for 5 h total, the last 3 h in the pres-
ence of Brefeldin A (5 μg/mL). Cells were finally fixed with 2%
formaldehyde, stained and analyzed by flow cytometry on BD LSR
II machine. Th17 cells, either untransduced or viral vector trans-
duced, were cultured with allogenic feeder cells in a 1:2 ratio
in the absence or in presence of exogenous recombinant IL-12
(2,5 ng/mL, R&D Systems). Following two weeks in culture
cells were harvested and frozen for subsequent mRNA expression
investigation.
DNA methylation analysis
Genomic DNAwas extracted by using DNA BloodMini kit (Qiagen,
Hilden, Germany) following manufacturer’s instructions. DNA
methylation analysis was performed by Varionostic GmbH (Ulm,
Germany). Briefly, genomic DNA was bisulfite converted by using
EZ DNAMethylation-GoldTM Kit (Zymo Research, Irvine, CA, USA)
following manufacturer’s instructions. Bisulfite converted DNA
was then PCR amplified at the different regions of interest of
IL17A, IL17F, IFNG, RORC2 and TBX21 genes by using bisulfite-
DNA specific primers. PCR products were then subjected to pyrose-
quencing. Primer sequences for bisulfite-PCR and sequencing have
already been described [16]. Methylation levels at CpG sites were
obtained by using PyroQ-CpG software as previously described
[43].
RNA isolation, cDNA synthesis and real-time
quantitative RT-PCR
Total RNA was extracted by using the RNeasy Micro Kit (Qiagen,
Hilden, Germany) and treated with DNase I to eliminate possible
genomic DNA contamination. RNA reverse transcription was per-
formed with Taqman Gold kit (Thermo Fisher Scientific). Briefly,
for the analysis of each gene expression, total mRNA recovered
from 104 cells was reverse transcribed and then subjected to RT-
PCR amplification. Ct values were then transformed into arbitrary
units (AU) using a standard curve generated with a reference sam-
ple. Primers and probes used were purchased from Thermo Fisher.
Confocal microscopy
Th17, non-classic and classic Th1 clones were resuspended in
complete medium (RPMI 1640) (2 × 105 /mL) and seeded on
polylysine-coated glass slides. Cells were then incubated for
40 min at 37 °C and 5% CO2, followed by 30 min incubation
with biotin-CD3 (eBiosciences) or control isotype. Following,
cells were washed in PBS pH 7.2 and incubated for 30 min with
Streptavidin 488 conjugated (1:200). Cells were then washed,
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fixed in formaldehyde (4% in PBS pH 7.2), permeabilized with
0.1% Triton (Sigma) for 10 min, and incubated for 20 min at
room temperature with goat serum (1 mg/mL). Cells were then
incubated with an anti-Eomes (Abcam 23345, 1:100) or control
isotype overnight at 4 °C. Following incubation with ab23345,
cells were washed and then incubated at room temperature
with anti-rabbit IgG Alexa Fluor 546 conjugated Ab for 30 min
(2 μg/mL), in buffer containing TOPRO-3 dye (0.2 μM) for
the nuclear counter staining. Cells were then washed in PBS
for 5 min, and the slides mounted with Vectashield mounting
medium (Vector Laboratories Inc., Burlingame CA). Microscopic
images were taken by a LSM 510 META Zeiss confocal microscope
system (Carl Zeiss Inc., Jena, Germany), using 40X oil immersion
lens, corresponding to a 400X magnification. For image analysis
Confocor 2 (Zeiss) software was used.
Chromatin immunoprecipitation
Th17 cell lines overexpressing Eomes were fixed with 1%
formaldehyde, followed by 0.125 M glycine incubation. Cells were
subsequently lysed with SDS Lysis Buffer to release chromatin,
which was then sheared by sonication. Anti-Eomes (ab23345,
Abcam) was added overnight at 4 °C. Unspecific IgG was used as
negative control. DNA–protein antibody complexes were immuno-
precipitated via protein A beads (Thermo Fisher). Cross-linking
was reversed by incubation at 65 °C for 4 h. ChIP DNA as well as
input DNAwas purifiedwith DNA extraction kit (Macherey Nagel).
Finally, real-time qPCR was performed to detect the abundance
of RORC2, IL17A and IL2 genes by using the following primers:
RORC2-F GGAGTCCCAGCAAGATCAGA; RORC2-R TTCAGGGCC
CCTCAGTATTC; IL17A-F GTGTCACCCCTGAACCCAC; IL17A-R
GAGATGGACAAAATGTAGCGCT; IL2-F CCTCAACTCCTGCCA-
CAATG; IL2-R CAGTAAATGCTCCAGTTGTAGCT. Genomic loca-
tion of amplicon products is reported in Supporting Information
Fig. 5.
Lentivirus transduction
PB-derived CD4+CD161+CCR6+CXCR3− cells were activated with
irradiated APCs plus anti-CD3 mAb (1 μg/mL). After 16 h,
pCCL-EF1α-NGFR, pCCL-EF1α-NGFR-RORC2, pCCL-EF1α-NGFR-
MSC or pCCL-EF1α-NGFR-EOMES lentivirus were added at a mul-
tiplicity of infection (MOI) of 10 and cells were inoculated at
1200 × g, 26 °C for 2 h. Transduced T cells were kept in culture
with IL-2 (100 U/mL, Eurocetus, Italy), purified after 5 days with
anti-NGFR-PE (BD Biosciences) plus anti-PE microBeads (Miltenyi
Biotec) achieving purities greater than 98%, and then maintained
in culture.
Microarray
Gene expression profiles on human Th1 and Th17 clones were
assessed by cDNA microarray technique using the SurePrint G3
Human GE v2 8 × 60 K Microarray (Agilent Technologies) as
previously described [37]. Cells were kept in culture in RPMI
1640 medium supplemented with 10% FCS and 50 IU/mL recom-
binanat human IL-2. Cells were then stimulated for 6 h with
anti-CD2+anti-CD3+anti-CD28 coated beads. Unstimulated con-
trol cells were also prepared in absence of the beads cocktail.
Total RNA was extracted using RNeasy Micro Kit (QIAGEN)
following manufacturer’s recommendations, quantified using a
NanoDrop-1000 spectrophotometer and quality-checked with an
Agilent 2100 Bioanalyzer. Total RNA was labelled with the
One Color (Cyanine 3-CTP) Low Input Quick Amp Labeling
Kit (Agilent Technologies) according to manufacturer protocol
and hybridized to the microarray chips according to specifi-
cations in One-Color Microarray-Based Gene Expression Anal-
ysis Protocol. Slides were scanned immediately after washing
on the Agilent DNA Microarray Scanner (G2565CA) using one
color scan setting for 8 × 60 K array slides (scan resolution
2 um/pixel). Imaging data was extracted using Agilent Fea-
ture Extraction Software version 10.7.3.1 with default param-
eters of protocol GE1 107 Sep09. Data preprocessing was per-
formed using R/Bioconductor (version 3.6) Agi4 × 44PreProcess
(version 1.22) package. Briefly, raw Feature Extractor data was
loaded into R and further background corrected (method = ”half”,
offset = 50), normalized (method = ”quantile”) and filtered
(wellaboveBG = 60, isfound = 60). Raw and processed data
have been deposited in the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/GEO) under the accession num-
ber GSE110230.
Gene expression profiles on Th17 cells transformed with
lentivirus to overexpress Eomes were assessed by cDNA microar-
ray technique using the Human Genome U133 Plus 2.0 GeneChips
(Affymetrix). RNA was prepared and quality checked as described
above. Labeling and hybridization was performed as per
Affymetrix’s standard protocols for this chip type. R/Bioconductor
(version 3.6) affy package (version 1.56) was used for qual-
ity control and preprocessing (RMA). Raw and processed data
have been deposited in the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/GEO) under the accession num-
ber GSE110545.
Differential expression (DE) analysis were performed with
limma package (version 3.34.6) considering DE signals with
abs(logFC)>1 and adjusted (Benjamini-Hochberg) p-value
< 0.05. Intersection analysis was drawn using the venn function
of the gplots package (version 3.0.1).
Evaluation of cytokines in supernatants
5 × 105 cells from three Th17, three Th1 non-classic and three
Th1 classic clones were stimulated, at final concentration of
1 × 106/mL, with anti-CD2, anti-CD3, anti-CD28 coated beads
(Miltenyi). After 3 days of culture, GM-CSF cytokine levels in
supernatants were evaluated by CBA flex set assay following the
manufacturer’s instructions (BD Bioscience).
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Colitis induction and tamoxifen treatment
RAG1−/− mice that were tested positive for SFB and Helicobacter
species (H. spp) were intravenously injected with 0,4× 106 in vitro
differentiated Eomesfl/flxRosa26:CreERT2 Th17 cells. Starting the
day after the T cell transfer and for the following 4 days, RAG1−/−
mice were intraperitoneally administered with 1 mg/mouse of
tamoxifen (Sigma-Aldrich) or vehicle (sunflower oil+ 10%EtOH).
As indication of disease activity, weight loss and diarrhea appear-
ance were monitored. RAG1−/− mice were sacrificed before losing
10% of body weight.
In vitro murine Th17 differentiation
Eomesfl/flxRosa26:CreERT2 mice were used as donors to obtain
CD4+CD62L+ na¨ıve T cells. Briefly, cells were isolated from the
spleen and single cell suspension was incubated with anti-CD4-
FITC (GK1.5) for 10 min on ice, washed and subsequently incu-
bated with anti-FITC microbeads (Miltenyi), according to manu-
facturer´s instructions. After washing away the bound microbeads
with Multisort Release Reagent (Miltenyi), the positive frac-
tion (purity  95%) containing CD4+ T cells was incubated
with anti-CD62L microbeads (Miltenyi), according to manufac-
turer´s instructions. CD4+CD62L+ na¨ıve T cells with were cul-
tured under Th17 polarizing conditions for a total of 10 days
[IL-6 (R&D) = 20 ng/mL; IL-23 (R&D) = 20 ng/mL; TGF-β
(R&D) = 2ng/mL; anti-IL-4 (11B11.2) = 10 μg/mL; anti-IFN-γ
(XMG1.2) = 10 μg/mL; anti-CD3 (BD Biosciences) = 1 μg/mL;
anti-CD28 (BD Biosciences) = 1 μg/mL]. In order to increase the
frequency of IL-17-secreting cells, at day 5 from starting of the
culture, Th17 cells were collected and re-plated under the same
polarizing conditions for additional 5 days. Frequency of IL-17-
secreting cells prior to T cell transfer was assessed upon in vitro
re-stimulation, as described.
Histopathology
Colons were fixed in 4% PFA at room temperature (RT) overnight
in the “Swiss roll” conformation. Colons were then washed in PBS,
embedded in paraffin and stained with hematoxylin and eosin.
Histopathology was scored according to a published disease score
[44].
Isolation of colonic leukocytes
Leukocytes were isolated from the colon of colitic RAG1−/− mice
as published elsewhere [44, 45]. Briefly, colons were cut longi-
tudinally, and fecal material was removed via washing in PBS. In
order to remove the epithelial layer, colons underwent 2 rounds of
incubation, each of 20 min at 37 °C, in Ca2+/Mg2+-free 1x HBSS
supplemented with 5 mM EDTA and 10 mM HEPES. After being
cut into small pieces, colons underwent 3 additional rounds of
digestion, each of 20 min at 37 °C, in 1x HBSS with Ca2+/Mg2+
supplementedwith 0.5mg/mLCollagenase D (Roche), 0.5mg/mL
DNAseI (Sigma-Aldrich), 0.5 U/mL Dispase (BD Biosciences) and
4 % FCS.
Flow cytometry and in vitro re-stimulation assay
Single cell suspensions of spleens and colons were incubated with
10 μg/mL anti-FCγRII/III (2.4G2) in FACS buffer (PBS/0.1%
BSA/2mM EDTA) for 10 min at +4°C. For surface staining, cells
were stained for 15 min at +4 °C with anti-CD3 (145-2C11),
anti-CD4 (RM4-5), anti-CD64 (X54-5/7.1), anti-Ly6C (HK1.4),
anti-Ly6G (1A8), anti-SiglecF (E50-2440). For staining of tran-
scription factors, cells were first fixed for 1 h at +4 °C with Foxp3
fixation/permeabilization working solution according to the man-
ufacturer’s instructions (eBioscience), washed with 1x permeabi-
lization buffer (eBioscience) and stained for 45 min at RT with
anti-RORγt (Q31-378). For intracellular staining of cytokines, cells
were first in vitro re-stimulated for 5 h at +37 °C, 5% CO2 with
PMA (10 ng/mL) and Ionomycin (1 μg/mL) in complete RPMI
1640 (ThermoFisher) supplemented with 10% FCS. Brefeldin A
(5 μg/mL) was added after the first 2 h. Cells were then fixed
in Cytofix/Cytoperm buffer (BD Biosciences) for 15 min at RT,
washed with 1x permeabilization buffer (BD Biosciences) and
intracellularly stained for 45 min at RT with anti-IFN-γ (XMG1.2)
and anti-IL-17A (TC11-18H10.1). Dead cells were excluded via
staining with LIVE/DEAD Fixable Dead Cell Stain prior to sur-
face staining or fixation (ThermoFisher). Stained samples were
acquired on MACSQuant (Miltenyi). Flow cytometric data were
analyzed with FlowJo softwares (FlowJo LLC). Flow cytometry
experiments were perfomed in agreement with flow cytometry
guidelines [46].
Statistics
Student’s t-test was used for mRNA expression analysis, confo-
cal microscopy experiments and ChIP studies. Mann-Whitney test
was used for DNA methylation. p values of 0.05 or less were con-
sidered significant. Pearson’s correlation coefficients were used to
calculate the correlations.
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